Columbia, MD (PRWEB) September 06, 2017
BioFortis, Inc. announced today that Mark Engelhart has joined its senior leadership team as the company’s Chief Commercial Officer, responsible for its sales and marketing functions.
Mr. Engelhart has over 25 years of experience in the Pharmaceutical and Contract Research Organization (CRO) industries, most recently serving as Chief Commercial Officer of ACM Global Laboratories.
“Mark brings a wealth of experience and knowledge of the biopharma, central lab, and CRO markets to his new role with BioFortis. His addition to our team will help us continue the strong growth we have experienced in providing complete biospecimen lifecycle management solutions, which has become a critical need for modern biomarker-driven clinical trials," said Jian Wang, BioFortis’ Chief Executive Officer. "His knowledge of the requirements and pressures our clients face, and his longstanding commitment to providing excellent service to clients, will help our team further strengthen our industry leading position.”
BioFortis is a leading provider of clinical development technology solutions which empower complete biospecimen lifecycle management. Its flagship product, Labmatrix, provides clinical trial sample & consent tracking, study subject & biobank management, and sophisticated data management capabilities leveraging the full potential of patient and sample-related information. With enterprise-level capabilities for integrating eClinical and bioresearch data collections in a harmonized, tightly-linked, and regulatory-compliant manner, Labmatrix empowers its users to easily ask sophisticated ad hoc questions and generate insights, reports, and dashboard visualizations. For more information, contact us at info(at)biofortis(dot)com, visit http://www.biofortis.com, or follow BioFortis on LinkedIn.